1
|
Manta K, Papakyriakopoulou P, Nikolidaki A, Balafas E, Kostomitsopoulos N, Banella S, Colombo G, Valsami G. Comparative Serum and Brain Pharmacokinetics of Quercetin after Oral and Nasal Administration to Rats as Lyophilized Complexes with β-Cyclodextrin Derivatives and Their Blends with Mannitol/Lecithin Microparticles. Pharmaceutics 2023; 15:2036. [PMID: 37631250 PMCID: PMC10459069 DOI: 10.3390/pharmaceutics15082036] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/24/2023] [Accepted: 07/26/2023] [Indexed: 08/27/2023] Open
Abstract
Quercetin (Que) is one of the most studied flavonoids with strong antioxidant properties ascribed to its ability to bind free radicals and inactivate them. However, the low solubility of the compound along with its inadequate absorption after oral administration limit its beneficial effects. Que's complexation with two different cyclodextrin (CD) derivatives (hydroxypropyl-β-CD and methyl-β-CD) via the neutralization/lyophilization method has been found to improve its physicochemical properties. Moreover, blends of the lyophilized powders with mannitol/lecithin microparticles (MLMPs) have been proposed as candidates for intranasal (IN) administration after in vitro and ex vivo evaluations. In this context, a comparative pharmacokinetic (PK) study of the IN vs oral administration of Que lyophilized powders and their blends with MLMPs (75:25 w/w) was performed on Wistar rats. The PK parameters estimated by a non-compartmental analysis using the sparse data methodology in Phoenix® 8.3 (Certara, Princeton, NJ, USA) illustrated the effectiveness of IN administration either in brain targeting or in reaching the bloodstream. Significant levels of the compound were achieved at both sites, compared to those after oral delivery which were negligible. These results favor the potential application of the prepared Que nasal powders for systemic and nose-to-brain delivery for the prevention and/or treatment of neuroinflammatory degenerative conditions, such as Parkinson's and Alzheimer's disease.
Collapse
Affiliation(s)
- Konstantina Manta
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece; (K.M.); (P.P.); (A.N.)
| | - Paraskevi Papakyriakopoulou
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece; (K.M.); (P.P.); (A.N.)
| | - Anna Nikolidaki
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece; (K.M.); (P.P.); (A.N.)
| | - Evangelos Balafas
- Laboratory Animal Facility, Centre of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece; (E.B.); (N.K.)
| | - Nikolaos Kostomitsopoulos
- Laboratory Animal Facility, Centre of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece; (E.B.); (N.K.)
| | - Sabrina Banella
- Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy; (S.B.); (G.C.)
| | - Gaia Colombo
- Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy; (S.B.); (G.C.)
| | - Georgia Valsami
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece; (K.M.); (P.P.); (A.N.)
| |
Collapse
|
2
|
Diefenthaeler HS, Bianchin MD, Marques MS, Nonnenmacher JL, Bender ET, Bender JG, Nery SF, Cichota LC, Külkamp-Guerreiro IC. Omeprazole nanoparticles suspension: Development of a stable liquid formulation with a view to pediatric administration. Int J Pharm 2020; 589:119818. [PMID: 32866648 DOI: 10.1016/j.ijpharm.2020.119818] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 08/02/2020] [Accepted: 08/23/2020] [Indexed: 12/14/2022]
Abstract
Omeprazole (OME) is often used to treat disorders associated with gastric hypersecretion in children but a liquid pediatric formulation of this medicine is not currently available. The aim of this study is to develop OME loaded nanoparticles with a view to the obtention of a liquid pharmaceutical dosage form. Eudragit® RS100 was selected as the skeleton material in the inner core and pH-sensitive Eudragit® L100-55 was used as the outer coating of the nanoparticles prepared by the nanoprecipitation method. Pharmacological activity was evaluated by induction of ethanol ulcers in mice. The OME nanoparticles exhibited mean diameters of 174 nm (±17), polydispersity index of 0.229 (±0.01), zeta potential values of -13 mV (±2.60) and encapsulation efficiency of 68.1%. The in vivo pharmacological assessment showed the ability of nanoparticles to protect mice stomach against ulcer formation. The prepared suspension of OME nanoparticles represents effective therapeutic strategy in a liquid pharmaceutical form with the possibility of pediatric administration.
Collapse
Affiliation(s)
- Helissara Silveira Diefenthaeler
- Programa de Pós-Graduação em Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil
| | - Mariana Domingues Bianchin
- Programa de Pós-Graduação em Ciências Biológicas: Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul, 90050-170 Porto Alegre, RS, Brazil
| | - Morgana Souza Marques
- Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil
| | - Julia Livia Nonnenmacher
- Faculdade de Farmácia, Universidade Regional Integrada do Alto Uruguai e das Missões, 99709-910 Erechim, RS, Brazil
| | - Emanueli Tainara Bender
- Faculdade de Farmácia, Universidade Regional Integrada do Alto Uruguai e das Missões, 99709-910 Erechim, RS, Brazil
| | - Júlia Gabrieli Bender
- Faculdade de Farmácia, Universidade Regional Integrada do Alto Uruguai e das Missões, 99709-910 Erechim, RS, Brazil
| | - Samara Feil Nery
- Faculdade de Farmácia, Universidade Regional Integrada do Alto Uruguai e das Missões, 99709-910 Erechim, RS, Brazil
| | - Luiz Carlos Cichota
- Faculdade de Farmácia, Universidade Regional Integrada do Alto Uruguai e das Missões, 99709-910 Erechim, RS, Brazil
| | - Irene Clemes Külkamp-Guerreiro
- Programa de Pós-Graduação em Nanotecnologia Farmacêutica, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Biológicas: Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul, 90050-170 Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil.
| |
Collapse
|
3
|
Abdel-Gawad R, Osman R, Awad GA, Mortada N. Lecithin-based modified soft agglomerate composite microparticles for inhalable montelukast: Development, tolerability and pharmacodynamic activity. POWDER TECHNOL 2020. [DOI: 10.1016/j.powtec.2019.11.029] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
4
|
Tiozzo Fasiolo L, Manniello MD, Bortolotti F, Buttini F, Rossi A, Sonvico F, Colombo P, Valsami G, Colombo G, Russo P. Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. J Drug Target 2019; 27:984-994. [PMID: 30691325 DOI: 10.1080/1061186x.2019.1574300] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Neuroinflammation occurs in the early stages of Alzheimer's disease (AD). Thus, anti-inflammatory drugs in this asymptomatic initial phase could slow down AD progression, provided they enter the brain. Direct nose-to-brain drug transport occurs along olfactory or trigeminal nerves, bypassing the blood-brain barrier. Nasal administration may enable the drug to access the brain. Here, flurbiprofen powders for nose-to-brain drug transport in early AD-related neuroinflammation were studied. Their target product profile contemplates drug powder deposition in the nasal cavity, prompt dissolution in the mucosal fluid and attainment of saturation concentration to maximise diffusion in the tissue. Aiming to increase drug disposition into brain, poorly soluble flurbiprofen requires the construction of nasal powder microparticles actively deposited in nose for prompt drug release. Two groups of powders were formulated, composed of flurbiprofen acid or flurbiprofen sodium salt. Two spray dryer apparatuses, differing for spray and drying mechanisms, and particle collection, were applied to impact on the characteristics of the microparticulate powders. Flurbiprofen sodium nasal powders disclosed prompt dissolution and fast ex vivo transport across rabbit nasal mucosa, superior to the acid form, in particular when the powder was prepared using the Nano B-90 spray dryer at the lowest drying air temperature.
Collapse
Affiliation(s)
- Laura Tiozzo Fasiolo
- a Department of Food and Drug, University of Parma , Parma , Italy.,b Department of Life Sciences and Biotechnology, University of Ferrara , Ferrara , Italy
| | | | - Fabrizio Bortolotti
- b Department of Life Sciences and Biotechnology, University of Ferrara , Ferrara , Italy
| | | | - Alessandra Rossi
- a Department of Food and Drug, University of Parma , Parma , Italy
| | - Fabio Sonvico
- a Department of Food and Drug, University of Parma , Parma , Italy
| | - Paolo Colombo
- a Department of Food and Drug, University of Parma , Parma , Italy.,d PlumeStars Srl , Parma , Italy
| | - Georgia Valsami
- e Department of Pharmacy, National and Kapodistrian University of Athens , Athens , Greece
| | - Gaia Colombo
- b Department of Life Sciences and Biotechnology, University of Ferrara , Ferrara , Italy
| | - Paola Russo
- c Department of Pharmacy, University of Salerno , Fisciano (SA) , Italy
| |
Collapse
|
5
|
Kolbina M, Bodmeier R, Körber M. Saturated phosphatidylcholine as matrix former for oral extended release dosage forms. Eur J Pharm Sci 2017; 108:86-92. [PMID: 28716757 DOI: 10.1016/j.ejps.2017.07.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 06/16/2017] [Accepted: 07/13/2017] [Indexed: 11/25/2022]
Abstract
The aim of this study was to evaluate the suitability of saturated phosphatidylcholine (Phospholipon® 90H) as extended release excipient in matrix tablets for three model drugs with different aqueous solubility (theophylline, caffeine and diprophylline). The tablets could be prepared by direct compression because of the favorable phospholipid powder flow properties (Carr's index: 12.64 and angle of repose: 28.85) and good compactibility. Tablets of low porosity were formed already at low pressure of 40MPa and with drug loadings up to 70% due to high plasticity of the phospholipid. Extended drug release was achieved with the drugs of different solubility and at various drug loadings. For example, the caffeine release time (t80%) from 8mm tablets ranged from 1.5h to 18h at 70% and 10% drug loading, respectively. The drug release was governed by diffusion and could therefore be modelled by Fick's law of diffusion. Drug release profiles were thus a function of drug solubility, drug loading and tablet dimension. Matrix tablets of caffeine (20% drug loading) showed robust dissolution with regard to agitation (50-100rpm) and ionic strength of the release media (100-600 mOsmol/kg). Caffeine release was pH-dependent with a faster drug release at acidic pH, which was attributed to a protonization of the phosphatidyl group of the matrix-former and thus a higher hydrophilicity.
Collapse
Affiliation(s)
- Marina Kolbina
- College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany
| | - Roland Bodmeier
- College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany
| | - Martin Körber
- Pensatech Pharma GmbH, Kelchstr. 31, 12169 Berlin, Germany.
| |
Collapse
|
6
|
From tablets to pharmaceutical nanotechnologies: Innovation in drug delivery strategies for the administration of antimalarial drugs. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2015.06.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
7
|
Otake H, Okuda T, Okamoto H. Development of Spray-Freeze-Dried Powders for Inhalation with High Inhalation Performance and Antihygroscopic Property. Chem Pharm Bull (Tokyo) 2016; 64:239-45. [DOI: 10.1248/cpb.c15-00824] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
8
|
Otake H, Okuda T, Hira D, Kojima H, Shimada Y, Okamoto H. Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device. Pharm Res 2015; 33:922-31. [DOI: 10.1007/s11095-015-1838-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 12/01/2015] [Indexed: 11/24/2022]
|
9
|
Layered lipid microcapsules for mesalazine delayed-release in children. Int J Pharm 2011; 421:293-300. [DOI: 10.1016/j.ijpharm.2011.09.043] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2011] [Revised: 09/22/2011] [Accepted: 09/27/2011] [Indexed: 01/29/2023]
|
10
|
Comparative study of preparation and characterization of enteric and enhanced release omeprazole microparticles. J Drug Deliv Sci Technol 2011. [DOI: 10.1016/s1773-2247(11)50079-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
11
|
El-Gendy N, Aillon KL, Berkland C. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int J Pharm 2010; 391:305-12. [PMID: 20214960 DOI: 10.1016/j.ijpharm.2010.03.009] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2009] [Revised: 02/23/2010] [Accepted: 03/01/2010] [Indexed: 11/25/2022]
Abstract
Aerosolized contrast agents may improve the resolution of biomedical imaging modalities and enable more accurate diagnosis of lung diseases. Many iodinated compounds, such as diatrizoic acid, have been shown to be safe and useful for radiographic examination of the airways. Formulations of such compounds must be improved in order to allow imaging of the smallest airways. Here, diatrizoic acid nanoparticle agglomerates were created by assembling nanoparticles into inhalable microparticles that may augment deposition in the lung periphery. Nanoparticle agglomerates were fully characterized and safety was determined in vivo. After dry powder insufflation to rats, no acute alveolar tissue damage was observed 2h post-dose. Diatrizoic acid nanoparticle agglomerates possess the characteristics of an efficient and safe inhalable lung contrast agent.
Collapse
Affiliation(s)
- Nashwa El-Gendy
- Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047, United States
| | | | | |
Collapse
|